Gathered together, this current extensive collection of evidence confirms CCR7 as key molecule in CLL and suggests, therefore, that tools targeting CCR7 are appealing as novel therapies in CLL. The gene discussed is CCR7; the disease is B-cell chronic lymphocytic leukemia.